法国ERYtech Pharma
法国ERYtech制药公司(ERYtech Pharma)创立于2004年11月，皮埃尔•奥利维尔•瓜诺先生(Pierre-Olivier Goineau)是公司董事会主席及联合创始人。
ERYTECH医药SA是法国后期阶段的生物制药公司发展为肿瘤的药用产品。该公司的专利核心技术的基础上使用，以改善人体红血细胞（红细胞）的药代动力学（PK）和药效学（PD）的治疗酶的特性（如天门冬酰胺酶）。

ERYTECH的主导产品，GRASPA®用于治疗急性淋巴细胞白血病（ALL）

ERYTECH Pharma creates high value products for hospital market, mainly in oncology, hematology and immunology fields.
Headquartered in France (Lyon) with a cGMP manufacturing unit, ERYTECH Pharma has a US Office and a US location for cGMP clinical batches production at the American Red Cross.

ERYTECH Pharma’s business & revenue model is both:
An integrated business & revenue model for proprietary product to maximize value creation
A business development revenue model based on its R&D platform and partnership